BCX7353: AN EFFECTIVE AND SAFE ORAL PROPHYLAXIS AGAINST ATTACKS OF HEREDITARY ANGIOEDEMA. APEX-1 FINAL RESULTS

被引：0
|
作者：
Aygoeren-Puersuen, E.
Bygum, A.
Panovska, V. Grivcheva
Steiner, U.
Huissoon, A.
Kinaciyan, T.
Fain, O.
Longhurst, H.
Farkas, H.
Fang, L.
Cornpropst, M.
Clemons, D.
Dobo, S.
Maurer, M.
Cicardi, M.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2017年 / 119卷 / 05期
关键词：
D O I：
10.1016/j.anai.2017.09.073
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P507
引用
收藏
页码：E4 / E4
页数：1
相关论文
共 31 条
  • [1] BCX7353, a once-daily oral kallikrein inhibitor, is effective and safe in the prophylaxis of acute attacks in patients with hereditary angioedema: Attack-level analysis of the APeX-1 study
    Aygoeren, E.
    Bygum, A.
    Steiner, U.
    Magerl, M.
    Panovska, Grivcheva, V
    Farkas, H.
    Huissoon, A.
    Graff, J.
    Lleonart, R.
    Rae, W.
    Aberer, W.
    Longhurst, H.
    Smith, W.
    Zanichelli, A.
    Cancian, M.
    Guilarte, M.
    Triggiani, M.
    Gompels, M.
    Fang, L.
    Cornpropst, M.
    Clemons, D.
    Collis, P.
    Dobo, S.
    Sheridan, W. P.
    Maurer, M.
    Cicardi, M.
    [J]. ALLERGY, 2017, 72 : 584 - 585
  • [2] Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial
    Longhurst, Hilary
    Moldovan, Dumitru
    Bygum, Anette
    Cicardi, Marco
    Huissoon, Aarnoud
    Aygoren-Pursun, Emel
    Grivcheva-Panovska, Vesna
    Hagin, David
    Steiner, Urs
    Stobiecki, Marcin
    Aberer, Werner
    Bethune, Claire
    Faust, Saul N.
    Kiani, Sorena
    Launay, David
    Maurer, Marcus
    Rae, William
    Reshef, Avner
    Cornpropst, Melanie T.
    Dobo, Sylvia M.
    VanDyke, Sharon
    Murray, Sharon
    Collis, Phillip J.
    Sheridan, William P.
    Farkas, Henriette
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB37 - AB37
  • [3] RELATIONSHIP OF TARGET CONCENTRATIONS WITH EFFICACY: RESULTS FROM THE APEX-1 STUDY OF BCX7353
    Farkas, H.
    Aygoren-Pursun, E.
    Panovska, V. Grivcheva
    Huissoon, A.
    Kinaciyan, T.
    Murray, S.
    Cornpropst, M.
    Sheridan, W.
    Maurer, M.
    Cicardi, M.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S33 - S33
  • [4] Long-term effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
    Reshef, A.
    Maurer, M.
    Kiani, S.
    Wu, A. Y.
    Stobiecki, M.
    Kinaciyan, T.
    Peter, J.
    Aygoren-Pursun, E.
    Cornpropst, M.
    Nagy, E.
    Murray, S.
    Collis, P.
    Farkas, H.
    [J]. ALLERGY, 2020, 75 : 210 - 211
  • [5] Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema
    Hwang, Jacqueline R.
    Hwang, Gloria
    Johri, Ansh
    Craig, Timothy
    [J]. IMMUNOTHERAPY, 2019, 11 (17) : 1439 - 1444
  • [6] Long-term safety and effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
    Kiani, Sorena
    Wu, Adrian
    Peter, Jonathan
    Reshef, Avner
    Maurer, Marcus
    Stobiecki, Marcin
    Kinaciyan, Tamar
    Aygoeren-Puersuen, Emel
    Best, Jessica
    Cornpropst, Melanie
    Sheridan, William P.
    Farkas, Henriette
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 172 - 173
  • [7] Final results from the ZENITH-1 study: Oral administration of plasma kallikrein inhibitor BCX7353 for the treatment of attacks in patients with hereditary angioedema
    Longhurst, H. J.
    Stobiecki, M.
    Zanichelli, A.
    Huissoon, A.
    Moldovan, D.
    Maurer, M.
    Magerl, M.
    Cancian, M.
    Senter, R.
    Manson, A.
    Aygoeren-Puersuen, E.
    Grivcheva-Panovska, V
    Hagin, D.
    Steiner, U.
    Kiani-Alikhan, S.
    Agmon-Levin, N.
    Bygum, A.
    Aberer, W.
    Faust, S. N.
    Launay, D.
    Gompels, M.
    Triggiani, M.
    Bethune, C.
    Reshef, A.
    Cornpropst, M.
    Dobo, S.
    Van Dyke, S.
    Murray, S.
    Collis, P.
    Sheridan, W. P.
    Farkas, H.
    Cicardi, M.
    [J]. ALLERGY, 2019, 74 : 10 - 11
  • [8] Long-term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX-S study results
    Farkas, H.
    Wu, A. Y.
    Kiani, S.
    Reshef, A.
    Stobiecki, M.
    Kinaciyan, T.
    Maurer, M.
    Aygoren-Pursun, E.
    Dix, D.
    Dobo, S.
    Iocca, H.
    Murray, S.
    Sheridan, W. P.
    Peter, J.
    [J]. ALLERGY, 2020, 75 : 58 - 59
  • [9] Preclinical Characterization of BCX7353, an Oral Plasma Kallikrein Inhibitor, for the Treatment of Hereditary Angioedema (HAE)
    Chen, Xilin
    Kotian, Pravin
    Wilson, Ramanda
    Parker, Cynthia D.
    Babu, Y. S.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB230 - AB230
  • [10] Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: Results from APeX-1 Study
    Steiner, U. C.
    Huissoon, A.
    Bygum, A.
    Panovska, V. G.
    Gompels, M.
    Cancian, M.
    Bova, M.
    Fain, O.
    Gobert, D.
    Guilarte, M.
    Smith, W. B.
    Kinaciyan, T.
    Graff, J.
    Fang, L.
    Clemons, D.
    Joseph, K.
    Murray, S.
    Collis, P.
    Sheridan, W.
    Cornpropst, M.
    Dobo, S.
    Aygoeren-Puersuen, E.
    Farkas, H.
    [J]. ALLERGY, 2018, 73 : 724 - 725
1234